Plasma Calcitonin in Paget's Disease of Bone

1977 ◽  
Vol 52 (3) ◽  
pp. 329-332 ◽  
Author(s):  
J. A. Kanis ◽  
G. Heynen ◽  
R. J. Walton
Keyword(s):  
Alkaline Phosphatase ◽  
Plasma Levels ◽  
Paget’S Disease ◽  
Paget's Disease ◽  
Paget’S Disease Of Bone ◽  
Paget's Disease Of Bone ◽  
Control Subjects ◽  
Plasma Alkaline Phosphatase ◽  
And Control ◽  
Age And Sex

1. Plasma levels of immunoreactive calcitonin were measured in 22 patients with untreated Paget's disease of bone and in 22 control subjects matched for age and sex. 2. No significant differences in plasma calcitonin were found between patients and control subjects, and hormone levels did not correlate significantly with activity of plasma alkaline phosphatase. 3. These results suggest that Paget's disease of bone is not due to deficient secretion of endogenous calcitonin.

Plasma α2 HS-glycoprotein Concentration in Paget's Disease of Bone: its Possible Significance

1980 ◽  
Vol 58 (5) ◽  
pp. 435-438 ◽  
Author(s):  
B. A. Ashton ◽  
R. Smith
Keyword(s):  
Alkaline Phosphatase ◽  
Plasma Concentration ◽  
Bone Formation ◽  
Alkaline Phosphatase Activity ◽  
Paget’S Disease ◽  
Paget's Disease ◽  
Paget’S Disease Of Bone ◽  
Paget's Disease Of Bone ◽  
Plasma Alkaline Phosphatase ◽  
Normal Adults

1. The plasma concentration of the α2HS-glycoprotein has been measured in 58 normal adults and in patients with Paget's disease of bone before (24) and during treatment (16). 2. The average plasma α2HS-glycoprotein was lower in the patients with Paget's disease than in the normal adults and was inversely related to plasma alkaline phosphatase activity (r = −0.55, n = 24, P<0.001). 3. When the patients with Paget's disease were treated with either diphosphonate or calcitonin, the plasma α2HS-glycoprotein concentration increased towards normal. In those patients treated with calcitonin, this increase was too rapid to be entirely accounted for by a cessation of bone formation.

Turnover rate of skeletal alkaline phosphatase in humans.

1982 ◽  
Vol 28 (1) ◽  
pp. 153-154 ◽  
Author(s):  
S Posen ◽  
H S Grunstein
Keyword(s):  
Alkaline Phosphatase ◽  
Half Life ◽  
Turnover Rate ◽  
Paget’S Disease ◽  
Paget's Disease ◽  
Paget’S Disease Of Bone ◽  
Paget's Disease Of Bone ◽  
Phosphatase Activities ◽  
Biological Half Life ◽  
Skeletal Alkaline Phosphatase

Abstract Two patients with Paget's disease of bone were subjected to plasmapheresis. Alkaline phosphatase activities of serum declined sharply, but returned to preplasmapheresis values within eight to 10 days. The biological half-life of circulating skeletal alkaline phosphatase, as calculated from these experiments, is between 1.12 and 2.15 days.

Comparison of Serum Osteocalcin with Total and Bone Specific Alkaline Phosphatase and Urinary Hydroxyproline: Creatinine Ratio in Patients with Paget's Disease of Bone

1994 ◽  
Vol 31 (4) ◽  
pp. 327-330 ◽  
Author(s):  
I M S Kaddam ◽  
S J Iqbal ◽  
S Holland ◽  
M Wong ◽  
D Manning
Keyword(s):  
Alkaline Phosphatase ◽  
Paget’S Disease ◽  
Paget's Disease ◽  
Paget’S Disease Of Bone ◽  
Serum Osteocalcin ◽  
Paget's Disease Of Bone ◽  
Urinary Hydroxyproline ◽  
Specific Alkaline Phosphatase ◽  
Bone Specific Alkaline Phosphatase ◽  
High Bone

Osteocalcin or bone Gla protein (BGP) is secreted by osteoblasts, and its serum concentration is elevated in a number of conditions with high bone turnover. A comparison of serum osteocalcin with total (TALP) and bone specific alkaline phosphatase (BALP) and urinary hydroxyproline/creatinine (OHP/Cr ratio) was performed in 13 patients with active Paget's disease of bone. BGP did not correlate significantly with either BALP or TALP, but did show a significant correlation with OHP/Cr ratio ( r = 0·76; P<0·01). BGP does not appear to be as sensitive a marker as BALP or TALP in Paget's disease.

scholarly journals Asymptomatic Paget's disease of bone in a 62-year-old Nigerian man: three years post-alendronate therapy

2016 ◽  
Vol 2016 ◽  
Author(s):  
Clement Olukayode Aransiola ◽  
Arinola Ipadeola
Keyword(s):  
Alkaline Phosphatase ◽  
Reference Range ◽  
Paget’S Disease ◽  
Elevated Serum ◽  
Paget's Disease ◽  
Paget’S Disease Of Bone ◽  
List Type ◽  
Paget's Disease Of Bone ◽  
Total Alkaline Phosphatase ◽  
Total Alkaline

Summary Paget's disease is a chronic and progressive disorder of bone characterized by focal areas of excessive osteoclastic resorption accompanied by a secondary increase in the osteoblastic activity. Paget's disease of bone (PBD) is a rare endocrine disease especially among Africans and Asians. Hence the detection of a case in a middle-aged Nigerian is of interest. We present the case of a 62-year-old Nigerian man in apparent good health who was found to have a markedly elevated serum total alkaline phosphatase (ALP) of 1179 U/l (reference range, 40–115 U/l) 4 years ago during a routine medical check-up in the USA. He had no history suggestive of PDB and also had no known family history of bone disease. Examination findings were not remarkable except for a relatively large head. A repeat ALP in our centre was 902 U/l (reference range, 40–120 U/l). Cranial CT scan showed diffuse cranial vault thickening consistent with Paget's disease which was confirmed by Tc-99m hydroxymethylene diphosphonate. He was placed on 40 mg alendronate tablets daily for 6 months. The patient has remained asymptomatic and has been in continuing biochemical remission during the 3-year follow-up period. The most recent ALP result is 88 U/l (reference range, 30–132 U/l) in April 2015. Learning points Serum total alkaline phosphatase remains a sensitive marker of bone turnover and an isolated increase above the upper limit of normal warrants more intense scrutiny in form of investigations targeted at excluding PD. Paget's disease is very rare but can occur in the Africans as seen in this Nigerian man and most patients are asymptomatic. Asymptomatic patients can benefit from treatment if disease is active, polyostotic or the lesions are located in bones with future risk of complications such as long bones, vertebrae and skull. Bisphosphonates are still the mainstay of treatment and alendronate is a useful therapeutic option for treatment.

scholarly journals P094 Incidence of clinically diagnosed Paget’s disease of bone: evidence of a continuing decline

Rheumatology ◽  
2021 ◽  
Vol 60 (Supplement_1) ◽  
Author(s):  
Michael J Cook ◽  
Stephen R Pye ◽  
William G Dixon ◽  
Terence W O'Neill
Keyword(s):  
Paget’S Disease ◽  
Paget's Disease ◽  
Paget’S Disease Of Bone ◽  
Paget's Disease Of Bone ◽  
Crude Incidence ◽  
Multiple Deprivation ◽  
The Uk ◽  
Incident Cases ◽  
Index Of Multiple Deprivation ◽  
Age And Sex

Abstract Background/Aims  Evidence from the UK suggest that the incidence of Paget's disease of bone declined during the latter half of the last century with a decline also in the incidence of clinically apparent disease. We aimed to characterise the recent incidence of clinically diagnosed Paget’s disease of bone in the UK by age and sex among those aged &gt;18 years and, to determine whether the incidence has changed from 1999-2015. Methods  Incident cases of Paget’s disease during 1999-2015 were identified from the first recorded diagnostic code for Paget’s disease in the UK Clinical Practice Research Datalink (CPRD) database. Crude incidence was calculated for each year from 1999 to 2015 and, to account for changes in the distribution of age and sex over time within the CPRD, direct age- and sex-standardised incidence rates were calculated for each year. This was done by multiplying the crude incidence in each age-sex stratum by the age-sex stratum weight of the 1999 population of those at risk of developing Paget’s disease. We looked also at the incidence of disease by quintile of index of multiple deprivation and geographic region. Using Poisson regression, we looked at the influence of deprivation and geography on occurrence of the disease after adjustment for age and sex. Results  In total 3,592 incident cases of Paget’s disease were identified between 1999 and 2015. Overall the incidence increased with age and at all ages was greater in men than women. In men, and women, respectively, incidence increased from 0.074 and 0.037 per 10,000 per year at the age of 45-49 years to 6.3 and 3.7 per 10,000 per year at age of 85 years and older. When stratified by year, the age- and sex-standardised incidence fell from 0.75/10,000 person years in 1999 to 0.20/10,000 person years in 2015. Crude incidence (1999-2015) was slightly higher in those living in the most deprived areas (0.53/10,000 person years) compared to those in least deprived areas (0.43/10,000 person years). After adjustment for age and sex, compared to those in the highest quintile of index of multiple deprivation, those in the lowest quintile of index of multiple deprivation had over a 30% increased risk of disease. There was evidence also of geographic variation in the occurrence of disease with the highest incidence in the North West of England. Conclusion  The incidence of clinically diagnosed Paget’s disease has continued to decrease since 1999. The reason for the decline remains unknown, though the rapidity of change points to an alteration in one or more environmental determinants. Disclosure  M.J. Cook: None. S.R. Pye: None. W.G. Dixon: None. T.W. O'Neill: None.

Sign in / Sign up

Export Citation Format

Share Document